We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-1.87%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.76B
AUM Growth
-$145M
Cap. Flow
-$29.4M
Cap. Flow %
-1.06%
Top 10 Hldgs %
57.66%
Holding
47
New
8
Increased
20
Reduced
5
Closed
10

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$92.2M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$63.9M
3
MDT icon
Medtronic
MDT
+$52.8M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$52.7M
5
ZIMV
ZimVie
ZIMV
+$47.1M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$98.8M
2
MRK icon
Merck
MRK
+$78.8M
3
GSK icon
GSK
GSK
+$65.2M
4
BIIB icon
Biogen
BIIB
+$60M
5
WBA
Walgreens Boots Alliance
WBA
+$54.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.18%
2 Technology 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTRS icon
1
Viatris
VTRS
$20.7B
$250M 9.05%
23,000,000
+7,000,000
+44% +$92.2M
UHS icon
2
Universal Health Services
UHS
$9.88B
$232M 8.39%
1,600,000
-50,000
-3% -$6.91M
SNY icon
3
Sanofi
SNY
$103B
$205M 7.43%
4,000,000
+200,000
+5% +$10.3M
ZBH icon
4
Zimmer Biomet
ZBH
$18.4B
$173M 6.25%
1,350,000
+320,000
+31% +$38.6M
GILD icon
5
Gilead Sciences
GILD
$163B
$149M 5.38%
2,500,000
+250,000
+11% +$16M
CHNG
6
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$131M 4.73%
6,000,000
+2,000,000
+50% +$41.5M
MRK icon
7
Merck
MRK
$321B
$123M 4.45%
1,500,000
-1,000,000
-40% -$78.8M
BKD icon
8
Brookdale Senior Living
BKD
$3.49B
$113M 4.08%
16,000,000
– –
IONS icon
9
Ionis Pharmaceuticals
IONS
$8.81B
$111M 4.02%
3,000,000
+1,610,000
+116% +$52.7M
WBA
10
DELISTED
Walgreens Boots Alliance
WBA
$107M 3.89%
2,400,000
-1,100,000
-31% -$54.1M
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.64B
$107M 3.89%
1,375,000
+550,000
+67% +$42.1M
INCY icon
12
Incyte
INCY
$24.9B
$107M 3.88%
1,350,000
+450,000
+50% +$32.7M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.7B
$100M 3.63%
1,300,000
+285,000
+28% +$23.8M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$98.7M 3.57%
1,200,000
+625,000
+109% +$63.9M
PRGO icon
15
Perrigo
PRGO
$1.43B
$96.1M 3.48%
2,500,000
+775,000
+45% +$29.5M
MYGN icon
16
Myriad Genetics
MYGN
$507M
$88.2M 3.19%
3,500,000
+750,000
+27% +$19.2M
PTCT icon
17
PTC Therapeutics
PTCT
$6.26B
$65.3M 2.36%
1,750,000
+1,000,000
+133% +$38.5M
THC icon
18
Tenet Healthcare
THC
$21.8B
$58M 2.1%
675,000
-525,000
-44% -$43.1M
MDT icon
19
Medtronic
MDT
$110B
$55.5M 2.01%
+500,000
New +$52.8M
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$49.1M 1.78%
+1,500,000
New +$44.5M
ZIMV
21
DELISTED
ZimVie
ZIMV
$45.7M 1.65%
+2,000,000
New +$47.1M
GSK icon
22
GSK
GSK
$104B
$43.6M 1.58%
800,000
-1,200,000
-60% -$65.2M
OSUR icon
23
OraSure Technologies
OSUR
$273M
$28.8M 1.04%
4,250,000
– –
NUVA
24
DELISTED
NuVasive, Inc.
NUVA
$28.4M 1.03%
500,000
+400,000
+400% +$21.2M
NBIX icon
25
Neurocrine Biosciences
NBIX
$18.7B
$28.1M 1.02%
+300,000
New +$25.4M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Camber Capital Management held 47 positions worth $2.76B, down 5% from $2.91B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Camber Capital Management's Q1 2022 filing shows 8 new, 20 increased, 5 reduced and 10 closed positions. Its largest new stake was Medtronic: 500,000 shares worth $55.5M. The largest sale was Vertex Pharmaceuticals, an estimated $98.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 86% a quarter earlier, followed by Technology.

  • Camber Capital Management's largest Q1 2022 buy was Medtronic: 500,000 shares worth $55.5M.
  • Camber Capital Management added most to Viatris in Q1 2022, an estimated $92.2M increase.
  • Camber Capital Management's biggest Q1 2022 reduction was Merck, cutting an estimated $78.8M.
  • Camber Capital Management fully exited Vertex Pharmaceuticals in Q1 2022, selling an estimated $98.8M.
  • Camber Capital Management's ten largest holdings make up 58% of its $2.76B portfolio in Q1 2022.
  • Camber Capital Management opened 8 new positions and closed 10 in Q1 2022.
  • Camber Capital Management's portfolio value fell 5% quarter-over-quarter to $2.76B.

Based on Camber Capital Management's 13F filing for Q1 2022, filed 16 May 2022.